ISSN: 2451-0629
Archives of Medical Science - Atherosclerotic Diseases
Current volume Archive About the journal Abstracting and indexing Contact Instructions for authors
Official journal of the International Lipid Expert Panel (ILEP)
CALL FOR PAPERS
1/2019
vol. 4
 
Share:
Share:
more
 
 
Letter to the Editor

Effect of 3-month α-lipoic acid treatment on sural nerve conduction velocity and amplitude in patients with diabetic neuropathy: a pilot study

Athanasia Papazafeiropoulou
,
Eleni Xourgia
,
Styliani Papantoniou
,
Aikaterini Trikkalinou
,
Andreas Melidonis 

Arch Med Sci Atheroscler Dis 2019; 4: e141–e143
Online publish date: 2019/07/18
Article file
- Effect of 3-month.pdf  [0.12 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Here we present our original research on the effects of α-lipoic acid, an emerging treatment option for the management of diabetic neuropathy, on nerve conduction parameters, an indirect marker of nerve functional integrity.

Diabetic neuropathy (DN) is a common complication of type 2 diabetes (T2D) with a major impact on the patient’s quality of life. Despite therapeutic advances, there are no agents targeting the main pathogenetic mechanisms of DN [1]. One of these is oxidative stress [2]. A-lipoic acid (ALA) seems to delay or reverse peripheral diabetic neuropathy through its multiple antioxidant properties [3]. Therefore, the aim of our study was to explore the effect of ALA treatment on the sural nerve conduction velocity (SNCV) and amplitude (SNAP) of T2D patients with DN.

Our sample consisted of 32 consecutive T2D patients (12 male), with mean age (± standard deviation) 67.9 ± 8.6 years, glycated hemoglobin (HbA1c) 7.1 ±1.0%, body mass index 30.7 ±11.2 kg/m² and T2D duration 14.1 ±5.3 years, attending the diabetes outpatient clinic of our hospital between September 2018 and February 2019. 72.7% of study patients were on oral antidiabetic medication and 26.5% on insulin therapy. Diagnosis of DN was based on the presence of at least one neuropathic symptom (burning, shooting pain, paraesthesia, muscle cramps or allodynia) in the lower extremities, and previous treatment for DN for ≥ 3 months before enrollment in the study [1]. Patients with causes of neuropathy other than diabetes (such as chronic alcohol misuse, vitamin B12 deficiency, drug-induced neuropathy), truncal neuropathy or severe neurological diseases (such as Parkinson’s disease and multiple sclerosis) and severe renal disease defined as estimated glomerular filtration rate (eGFR)  <  30 ml/min/1.73 m2 were excluded from the study. Regarding the other micro- and macrovascular diabetic complications, 14.3% of study patients had retinopathy, 28.6% chronic kidney disease, 18.2% coronary artery disease, and 47.6% peripheral arterial disease.

Participants were prescribed 600 mg/day ALA (Combinerv), to be administered orally, for 3 months, and were advised not to discontinue any other medication for DN, antidiabetic drugs, or substances used for managing arterial hypertension or dyslipidemia during the study. All study patients underwent a complete clinical examination and measurement of SNCV and SNAP using the NCstat DPNCheck test (NeuroMetrix, Inc., Waltham, MA) at study entry and after 3 months of ALA treatment. The NC-stat DPNCheck test has been assessed as both reliable and valid, and has the potential to be suitable for clinical applications [4]. Neuropathy was assessed using the Neuropathy Symptom Score (NSS) and the Neuropathy Disability Score (NDS) questionnaires at study entry and 3 months later [1].

The study was approved by the Ethics Committee of General Hospital of Piraeus “Tzaneio”, and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.

Data were analyzed using SPSS software, version 22.0 (IBM, Armonk, NY, USA) for Windows. Continuous variables are presented as mean ± SD. Nominal variables are presented as n (%) prevalence or frequencies. Student’s t-test was used to compare total scores/measurements between the baseline and 2nd visit. All tests were two-sided with α = 0.05. A p-value  ≤  0.05 was considered statistically significant.

At study entry, mean SNCV and SNAP were 45.5 ±17.6 m/s and 3.3 ±1.5 µV, respectively. After 2 months of α-lipoic acid treatment, SNCV and SNAP were 41.1 ±16.0 m/s and 4.1 ±1.6 µV, respectively. There were no statistically significant differences between SNCV and SNAP at study entry and after 3 months of ALA treatment. At study entry, NSS and NDS scores were 8.6 ±2.7 and 5.4 ±1.2, respectively. After 3 months of ALA treatment, NSS and NDS scores were 5.6 ±2.1 and 5.5 ±1.1, respectively. Only the observed decrease in NSS score was statistically significant (p = 0.05). No side effects were detected at the end of the study.

The results of the present study showed no effect of 3-month ALA treatment on SNCV and SNAP. In fact, there is no current evidence regarding an effective therapy for enhancing peripheral nerve function in patients with DN although a recent review showed that several treatments, including ALA, are effective in improving DN symptoms [4, 5]. In accordance with the above, a multicenter study for the evaluation of the efficacy and safety of ALA over 4 years in mild-to-moderate diabetic distal symmetric sensorimotor polyneuropathy showed that treatment with ALA did not influence neurophysiologic tests, but showed clinically meaningful improvement of neuropathic impairments [6]. However, a study in 50 patients with T2D and a deficit in both motor and sensory nerve conduction showed that after 4 months of treatment with ALA, patients significantly improved their electroneurographic parameters and their perception of pain [7]. The best improvements were observed in sensory nerve conduction [7]. Another study, in 30 patients with T2D with symptoms of DN for ≥ 6 months, showed that the combination of ALA with methylcobalamin and pregabalin resulted in improvement of nerve function [8]. In addition, a study in 24 male Wistar rats with DN showed that 2 weeks of treatment with ALA significantly increased nerve conduction velocity and amplitude [9]. In contrast, another study using diabetic rats showed that ALA treatment had no effect on sensory tests or on antioxidant activity [10].

It is obvious that the existing literature data on the effect of ALA on peripheral nerve function are still limited and controversial, with some studies showing a beneficial effect and others a neutral effect. At this point, it must be mentioned that our study has some limitations. First of all, we did not have a control group and patient’s compliance with the study agent was not assessed. Secondly, the sample was small, and the duration of the study short. Therefore, our results should be interpreted with reservation.

In conclusion, ALA treatment failed to improve SNCV and SNAP in T2D patients with DN. Interestingly, α-lipoic acid treatment induced an improvement only in NSS score. Longer patient follow-up might be necessary to show the favorable effect of ALA on DN.

Conflict of interest

The authors declare no conflict of interest.

References

1 

Boulton AJ, Vinik AI, Arezzo JC, et al. , authors. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005. 28:p. 956–62

2 

Brownlee M , author. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005. 54:p. 1615–25

3 

Nagamatsu M, Nickander KK, Schmelzer JD, et al. , authors. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 1995. 18:p. 1160–7

4 

Chatzikosma G, Pafili K, Demetriou M, Vadikolias K, Maltezos E, Papanas N , authors. Evaluation of sural nerve automated nerve conduction study in the diagnosis of peripheral neuropathy in patients with type 2 diabetes mellitus. Arch Med Sci. 2016. 12:p. 390–3

5 

Lee CC, Perkins BA, Kayaniyil S, et al. , authors. Peripheral neuropathy and nerve dysfunction in individuals at high risk for type 2 diabetes: the PROMISE cohort. Diabetes Care. 2015. 38:p. 793–800

6 

Ziegler D, Low PA, Litchy WJ, et al. , authors. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011. 34:p. 2054–60

7 

Bertolotto F, Massone A , authors. Combination of alpha lipoic acid and superoxide dismutase leads to physiological and symptomatic improvements in diabetic neuropathy. Drugs R D. 2012. 12:p. 29–34

8 

Vasudevan D, Naik MM, Mukaddam QI , authors. Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. [MAINTAIN]: results of a pilot study. Ann Indian Acad Neurol. 2014. 17:p. 19–24

9 

Seyit DA, Degirmenci E, Oguzhanoglu A , authors. Evaluation of electrophysiological effects of melatonin and alpha lipoic acid in rats with streptozotocine induced diabetic neuropathy. Exp Clin Endocrinol Diabetes. 2016. 124:p. 300–6

10 

Lee KA, Lee NY, Park TS, Jin HY , authors. Comparison of peripheral nerve protection between insulin-based glucose control and alpha lipoic acid (ALA) in the streptozotocin (STZ)-induced diabetic rat. Endocrine. 2018. 61:p. 58–67

Copyright: © 2019 Termedia & Banach. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe